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Abstract: Aquaporins (AQPs) are water channel proteins robustly expressed in the central nervous
system (CNS). A number of previous studies described the cellular expression sites and investigated
their major roles and function in the brain and spinal cord. Among thirteen different mammalian
AQPs, AQP1 and AQP4 have been mainly studied in the CNS and evidence has been presented
that they play important roles in the pathogenesis of CNS injury, edema and multiple diseases
such as multiple sclerosis, neuromyelitis optica spectrum disorders, amyotrophic lateral sclerosis,
glioblastoma multiforme, Alzheimer’s disease and Parkinson’s disease. The objective of this review
is to highlight the current knowledge about AQPs in the spinal cord and their proposed roles in
pathophysiology and pathogenesis related to spinal cord lesions and injury.
Keywords: aquaporin; spinal cord; astrocytes; neurons; endothelial cells; central nervous system;
peripheral nerve
1. Introduction
Since their discovery, aquaporin (AQP) water channels have gained a lot of attention.
Their prominent expression and important function have been identified in several organs in the body,
including kidney, salivary glands, muscle, lungs and central nervous system (CNS). AQPs display
high capacity as well as selectivity for transporting water molecules across cell membranes [1–4].
AQPs are highly conserved and often classified into classical AQPs selectively permeable to water
(AQP0, 1, 2, 4, and 5) and aquaglyceroporins with permeability to water, glycerol, and urea (AQP3, 7,
9, and 10) [5,6]. Furthermore, another group of so-called unorthodox AQPs has been distinguished,
since their physiological roles are not well characterized (AQP6, 8, 11, and 12) [7].
The function of AQPs for osmotic water transport is influenced by the structural hourglass form.
At the aromatic/arginine filter, the narrowest region of the pore (~2.8 Å), molecules larger than water
are excluded from passage through classical AQPs [8,9]. AQP monomers are built up by six membrane
spanning helical domains that surround this aqueous pore and are super-assembled in membranes
as tetramers. Thereby, in contrast to many ion channels like potassium or cyclic nucleotide-gated
channels where the pore resides at the center of the tetramer, each monomer acts as a functioning
water channel [10]. Moreover, AQP selectivity is enhanced by steric and electrostatic factors, since
the monomeric helices placed on the outside face of the tetramer are hydrophobic, whereas the
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hydrophilic ones are positioned close to the tetramer center [11,12]. Interestingly, in aquaglyceroporins
the narrowing of the pore is less constricted (~3.4 Å) and lined by more hydrophobic residues [13].
In the CNS, mRNA amplification of AQP1, 3, 4, 5, 8, 9 and 11 was reported [14,15]. However,
most studies in the brain or spinal cord have been limited to AQP1, 4 and 9 [16,17]. The most
extensively studied site of AQP expression in the brain is the ventricular system (Table 1). Choroid
plexus, enclosed in brain ventricles shows high abundance of AQP1 at the apical surface of the
epithelial cells [16]. Therefore, this channel is involved in the secretion of cerebrospinal fluid (CSF) [18].
The cerebrovascular endothelium in the CNS lacks AQP1 [16,19] with the exception of the blood
vessels in circumventricular organs [20] and small capillaries occasionally found in the brain and
spinal cord parenchyma [20–22]. Outside of the brain, AQP1 expression was found in the dorsal
horns of the spinal cord, in the dorsal root ganglia and its projecting nerves, particularly in the sciatic
nerve (Table 1) [14,21,23]. A portion of AQP1 labeling in spinal cord was assigned to a population
of the primary sensory neurons with small-diameter which are important in nociception and pain
processing [21,23]. Moreover, other studies suggested a role of this water channel in the perception of
inflammatory thermal pain and cold pain perception [24,25].
AQP4 is a water channel that is widely expressed throughout the CNS, particularly in astrocyte
processes building up the glial-limiting membrane and astrocytes that are in contact with endothelial
cells of the blood brain barrier (BBB) (Table 1). Furthermore, the presence of AQP4 was reported in
subependymal astrocytes and in the basolateral membrane of ependymal cells forming an interface
between CSF and CNS [17,26]. Strong AQP4 expression at the borders between brain parenchyma
and major fluid compartments, e.g., between brain ventricles and glia limitans externa or at the
BBB, suggests that AQP4 functions in facilitating water flow into and out of the brain and spinal
cord. Moreover, an increased AQP4 expression has been demonstrated in glioblastoma multiforme,
suggesting it is also involved in malignant brain tumors [27]. Although water transport can occur
to a certain extent through simple diffusion across the plasma membrane [28], studies utilizing
AQP4 knockouts demonstrated great importance of this water channel in the pathogenesis of
brain water imbalance and CNS injuries. In disease models of obstructive hydrocephalus, focal
cortical-freeze injury, brain tumor and intraparenchymal saline infusion, AQP4-deficient mice showed
more severe hydrocephalus, markedly increased intracranial pressure, limited water elimination
and poor neurological scoring when compared with their wild-type corresponding controls [29–31].
In contrast, several other reports concluded that AQP4-knockout mice possessed better survival
rate and improved neurological outcomes compared with wild-type controls exposed to cytotoxic
brain edema [32,33]. Complicated temporal and dimensional expression of AQP4 in different disease
conditions with different onset time of injury make it difficult to distinguish between beneficial and
disadvantageous roles of AQP4, since it may concurrently facilitate edema fluid clearance in one area
of the brain while intensifying accumulation of water in another region [33–35].
In addition, it was also demonstrated that AQP9 is expressed in the murine CNS (Table 1),
especially within midbrain catecholaminergic neurons [36] and rat subset of dopaminergic neurons
and astrocytes [37]. However, another study exploiting Aqp9 gene knockout mice found no evidence
of AQP9 expression in the brain [38]. The objective of this article is to review the current knowledge
regarding spinal cord AQPs expression in normal and pathological conditions, in order to analyze
their possible function and pathophysiological importance as well as to explore novel research areas
involving AQPs in the spinal cord and brain.
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Table 1. Comparison of AQP1, AQP4, AQP9 and AQP11 expression between spinal cord and brain cells and structures.
Spinal Cord Brain
Aquaporin (AQP) Cell Type and/or Structure Detection Method and Reference Cell Type and/or Structure Detection Method and Reference
AQP1
Unmyelinated sensory fibers in DH
Myelinated neuronal fibers (sparse) in DH (#)
Lamina V and X
Endothelial cells of small penetrating arterioles in
immediate vicinity to the glia limitans (sparse, #)
Astrocytes and ependymal cells (#)
IHC, RT-PCR, WB [23,24,39]
IHC [23]
IHC [14,21]
IHC [21]
IHC [39]
Epithelial cells of choroid plexus
Endothelial cells of circumventricular organs
Endothelial cells in blood vessels in brain
parenchyma (sparse, #)
Astrocytes, schwann cells surrounding the
oculomotor and trigeminal cranial nerve fibers,
neurons on the surface
of the pia blood vessels (#)
WB, IHC, IMEM [16,18]
IHC, RT-PCR [20]
IHC [20,22]
IHC [40–42]
AQP4
Astrocytes end-feet encircling capillaries, and
building up the glia limitans, processes
enveloping myelinated neuronal fibers;
Expression polarized to foot-processes in
protoplasmatic astrocytes and more evenly
distributed in fibrous astrocytes
IHC, RT-PCR, WB [14,21,43,44]
Subpial astrocytes processes forming glia
limitans, perivascular astrocyte endfeet in
cortex; expression highly polarized to
astrocytes foot-processes
Basolateral membrane of ependymal cells
IHC, IMEM, NB, RT-PCR, WB,
[17,26,43,45–48]
WB, IHC, IMEM [17,26]
AQP9 Astrocyte processes in white matterand glia limitans (#) IHC, RT-PCR, WB [14,40]
Neurons, ependymal cells (#), tanycytes (#)
Astrocytes mitochondria and astrocytes in the
immediate vicinity to subarachnoid space and
ventricles (#)
IHC, RT-PCR, WB [37,38,40,49–53]
IHC, RT-PCR [36–38,52]
AQP11 Not investigated Not investigated
Dendrites of Purkinje cells in cerebellum,
neurons in hippocampus and cerebral cortex (#)
Epithelium of the choroid plexus and at the
endothelium of the brain capillary (#)
IHC, NB, RT-PCR, WB [15,54]
IHC, RT-PCR, WB [55]
WB: Western blotting, IHC: Immunohistochemistry, IMEM: Immunoelectron Microscopy, NB: Northern blotting, RT-PCR: Reverse transcriptase polymerase chain reaction, DH: Dorsal
horn. Data marked with # are not fully confirmed and require further investigation.
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2. Expression Pattern of Aquaporins (AQPS) in the Healthy Spinal Cord
2.1. Aquaporin 1 (AQP1)
AQP1 expression in the brain was mostly assigned to epithelial cells of choroid plexus [16,18],
whereas the labeling pattern of AQP1 in the spinal cord is different. Essentially, AQP1 expression at
cervical, thoracic and lumbar level of the spinal cord posesses a very uniform pattern. The dorsal horn
in laminae I and II is especially rich with AQP1 spotted labeling (Figure 1A,D). AQP1 immunolabeling
in the dorsal horns was mostly assigned to the unmyelinated sensory fibers with small diameter [24,39]
(Figure 1B), and very few myelinated neurons [23]. Intense AQP1 labeling was found in synaptical
terminal membranes, but not in the area of synaptic density [23] (Figure 1C). In laminae III and IV,
AQP1 was dominantly present at the lateral and medial boundaries of the dorsal horns and in lamina
V, a tangled, filamental pattern of AQP1 immunolabeling was seen [21]. In contrast, in other parts of
gray matter AQP1 was pretty scarce with slightly increased expression in the immediate surroundings
of the central canal [14,21].
Shields et al. [23] reported complete lack of AQP1 mRNA in the spinal cord and concluded that
all AQP1 immunlabeling belongs to sensory neurons projecting form the dorsal root ganglion to
the spinal cord dorsal horn (Figure 1C). AQP1 expression showed a 92% overlap with peripherin,
a marker for small-diameter nociceptors in the dorsal root ganglion [25,56]. However, much less
co-localization between these two proteins was observed in the spinal cord [21]. Therefore, further
studies are necessary to precisely define the localization of AQP1 in the spinal cord dorsal horns.
Sparse and intermittent AQP1 labeling was found in immediate vicinity to the glia limitans
at all levels of the spinal cord, which is apparently associated with small penetrating arterioles
protruding from arterial vasocorona encountered in both white and gray matter (Figure 1E–G) [21].
These observations are in agreement with sporadical labeling of blood vessels in parenchyma of rat
and human brains [20,22]. However, these observations seem to be exceptional since in general AQP1
is not expressed in the capillaries of neurovascular units and BBB [16,19,57]. Aside from these cases,
one study reported AQP1 expression in astrocytes and ependymal cells in rat spinal cords [39].
2.2. Aquaporin 4 (AQP4)
AQP4 labeling has been found in astrocytes of the white and gray matter along the whole spinal
cord (Figure 2A). Fibrous astrocytes in spinal cord white matter are arranged in a radial pattern,
with AQP4-labeled astrocyte processes stretching from gray matter to glia limitans (Figure 2A,D).
Strong AQP4 immunolabeling is present in astrocytic end-feet encircling capillaries and building
up the glia limitans (Figure 2A). In addition, substantial AQP4 signal was found in astrocyte
processes enveloping myelinated neuronal fibers in longitudinal spinal cord white matter sections
(Figure 2E) [43]. AQP4 signal within the white matter is also intense and colocalized with commonly
used astrocyte markers, such as glial fibrillary acidic protein (GFAP) and glial glutamate transporter-1
(GLT-1) [14,21,44]. In gray matter AQP4 labeling was demonstrated in a distinctive laminar pattern
with strong intensity in the laminae I and II of the dorsal horn (Figure 2A), whereas, in the deeper
laminae, immunoreactivity decreased to moderate levels. However, labeling was slightly higher
in lamina X surrounding the central canal, the medial section of the dorsal horn neck and at the
thoracic level in the intermediolateral column. Moreover, in the gray matter more pronounced
immunlabeling was detected around blood vessels (often in the form of complete rings encircling the
blood vessels), neuronal perykarya and processes, especially in the superficial laminae of the dorsal
horns (Figure 2B,C). A more filamentous and spotted pattern of AQP4 surrounding dendrites, neuropil
and motor neurons was also observed in the ventral horns [14,21,44]. AQP4 labeling in spinal cord
protoplasmatic astrocytes was slightly more polarized compared to white matter fibrous astrocytes
(Figure 2C,E). Co-localization studies have shown less intense overlap between GFAP and AQP4,
primarily in laminae I and II of dorsal horns and in perivascular end-feet [21,43]. On the other hand,
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GLT-1 colocalized with AQP4 especially in gray matter neuropil, at fine astrocyte protrusions around
synaptic contacts, dendrites and perikarya [44].Int. J. Mol. Sci. 2016, 17, 2050 5 of 17 
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fibers (C); Illustration of AQP1 expression in the spinal cord cross-section (D); AQP1 labeling in the 
white matter was rather infrequent and found in proximity to the glia limitans (E) most likely 
belonging to small arterioles furcating from the arterial vasocorona (F,G). Panels A, B, E and F are 
modified from Oklinski et al. [21]. The blue signal in panels B and F represents 4′,6-diamidino-2-
phenylindole (DAPI) staining of the nuclei; AQP1, aquaporin 1; PERIPH, peripherin and RECA, rat 
endothelial cell antigen-1. Colocalization indicated by arrows. AQP1 is indicated in red on panels C, 
D and G. AQP4 is drawn in green on panel G. White arrows in B and F. 
There are two dominant AQP4 isoforms present in the CNS, M1 (323 amino acids) and the 
shorter M23 isoform (301 amino acids). Both types form homo- and hetero-tetramers and are highly 
water permeable [45,58]. The M23 isoform is required for the formation of higher order structures, 
known as square arrays [46,47]. Square arrays are predominantly found at astrocytic end-feet that 
form a continuous sheet surrounding blood vessels and glia limitans in the CNS [17,48]. In the 
protoplasmatic astrocytes of the spinal cord gray matter, AQP4 square arrays were found mostly in 
perivascular regions and their distribution resembles that reported in the brain cortical gray matter. 
Figure 1. AQP1 expression in the spinal cord. AQP1 was strongly expressed at laminae I and II of the
dorsal horn with decreasing signal intensity at the medial edges of dorsal horns up to lamina V (A,D);
A fraction of the AQP1 signal belonged to unmyelinated neuronal cells (B) protruding from dorsal root
ganglion to the superficial laminae of dorsal horns which axons build up peripheral sensory fibers
(C); Illustration of AQP1 expression in the spinal cord cross-section (D); AQP1 labeling in the white
matter was rather infrequent and found in proximity to the glia limitans (E) most likely belonging to
small arterioles furcating from the arterial vasocorona (F,G). Panels A, B, E and F are modified from
Oklinski et al. [21]. The blue signal in panels B and F represents 4′,6-diamidino-2-phenylindole (DAPI)
stai ing of the nuclei; AQP1, aquaporin 1; PERIPH, peripherin and RECA, rat en othelial cell antigen-1.
Colocalization indicated by arrows. AQP1 is indicated in red o p els C, D and G. AQP4 is drawn in
green on panel G. White arrows in B and F.
There are two dominant AQP4 isoforms present in the CNS, M1 (323 amino acids) and the
shorter M23 isoform (301 amino acids). Both types form homo- and hetero-tetramers and are highly
water permeable [45,58]. The M23 isoform is required for the formation of higher order structures,
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known as square arrays [46,47]. Square arrays are predominantly found at astrocytic end-feet
that form a continuous sheet surrounding blood vessels and glia limitans in the CNS [17,48].
In the protoplasmatic astrocytes of the spinal cord gray matter, AQP4 square arrays were found
mostly in perivascular regions and their distribution resembles that reported in the brain cortical gray
matter. However, in white matter, sizable clusters of AQP4 were observed in both parenchymal and
perivascular regions. Moreover, both white matter regions possess similar numbers of AQP4 square
arrays [43].
A relevant aspect of AQP4 and other AQPs expression in different parts of CNS are potentially
due to species differences in human and rodent astrocytes. Compared to mice, rat astrocytes express
higher levels of intermediate filament proteins such as GFAP, nestin and vimentin. Furthermore, S100β
a glial-specific calcium binding protein that is frequently used as an astrocyte marker, is expressed at
higher levels in rat astrocytes [59,60]. Moreover, rat astrocyte ultrastructure resembles the structure of
human astrocytes more closely than their murine equivalents [61,62], which needs to be considered
when analyzing and comparing AQPs expression data between different species.
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As in the brain, expression of AQP9 in spinal cord is still a matter of ongoing research. Earlier 
studies provided data about distinct AQP9 immunolabeling in ependymal cells, tanycytes and 
neurons in the rat brain [49,50], and astrocytic processes bordering the subarachnoid space and 
ventricles in the mouse brain [51]. In the spinal cord, immunolabeling was observed in particular in 
white matter and glia limitans astrocyte processes [14]. An ultrastructural analysis of rat brain 
performed by Amiry-Moghaddam et al. [37] suggested AQP9 expression in mitochondrial inner 
membrane of astrocytes and dopaminergic neurons in the substantia nigra and ventral tegmental 
area. However, as was found in the brain, immunolabeling in the spinal cord was undetectable when 
Figure 2. AQP4 expression in the spinal cord. AQP4 was abundantly expressed across the whole spinal
cord with markedly higher intensity in the superficial lamina of dorsal horns, verges of ventral horns,
glia limitans and surroundings of blood vessels (A); In the gray matter, protoplasmatic astrocytes AQP4
expression represents a polarized pattern with the highest intensity in the astrocytes foot processes
encircling capillaries (B,C) and weaker labeling in processes belonging to the tripartite synapse (C);
In the white matter, fibrous astrocytes AQP4 expression is observed along the cell membrane (D,E);
Illustrations of AQP4 expression in the spinal cord (C,E) markings in green illustrate AQP4. The blue
signal in panels B and D represents DAPI staining of the nuclei. Immunoperoxidase staining of AQP4
(A) and immunofluorescence images (B,D) are modified from Oklinski et al. [21]. AQP4, aquaporin 4;
GS, glutamate synthase.
2.3. Aquaporin 9 (AQP9)
As in the brain, expression of AQP9 in spinal cord is still a matter of ongoing research.
Earlier studies provided data about distinct AQP9 immunolabeling in ependymal cells, tanycytes
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and neurons in the rat brain [49,50], and astrocytic processes bordering the subarachnoid space and
ventricles in the mouse brain [51]. In the spinal cord, immunolabeling was observed in particular
in white matter and glia limitans astrocyte processes [14]. An ultrastructural analysis of rat brain
performed by Amiry-Moghaddam et al. [37] suggested AQP9 expression in mitochondrial inner
membrane of astrocytes and dopaminergic neurons in the substantia nigra and ventral tegmental
area. However, as was found in the brain, immunolabeling in the spinal cord was undetectable when
suitable positive and negative controls i.e., Aqp9 gene knockout mice were used [38]. Subsequent
detailed studies in rats and knockout mice conducted by Mylonakou et al. [52] reported limited
presence of both AQP9 mRNA and protein in mouse and rat brains in neuronal cells, but expression
in astrocytes remained elusive, because of nonspecific affinity of the utilized anti-AQP9 antibody
to GFAP. The localization in neurons was confirmed in later reports, where the data of astrocytic
AQP9 expression were acquired with the same antibody which Mylonakou had used [40]. Moreover,
it was also demonstrated that AQP9 mRNA levels in the brain are substantially lower compared to
the expression in liver. Furthermore, the observed expression level in mouse brain is about six times
lower compared to rat brain [52]. Recent systemic data gathered from human samples revealed that
AQP9 mRNA is expressed at very low levels in brain [53]. Despite some progress made for clarifying
the true expression of AQP9 in the brain, the data on the potential presence and localization of this
aquaglyceroporin in spinal cord remain limited. Ubiquitous expression of this channel has been
suggested in fibrous white matter of spinal cord astrocyte processes, reaching to glia limitans, central
canal and dorsal horn [14,40]. However, these reports need to be treated cautiously, considering that
AQP9 expression in brain astrocytes also remains controversial.
3. AQP Expression in Disease Conditions of Spinal Cord
3.1. Aquaporin 1 (AQP1)
3.1.1. AQP1 in Spinal Cord Injury (SCI) and Edema
The number of reports studying the expression of AQP1 in disease conditions of the spinal cord
is still quite limited. Nonetheless, two studies described a significant up-regulation (up to eight-fold
increase) of AQP1 in response to SCI at the injury site, with gradually decreasing expression extending
into the caudal and rostral direction [39,63]. AQP1 up-regulation was detected as early as 6 h after
injury [64] and persisted for up to 11 months [39]. AQP1 expression post injury was assigned to the
membranes of dorsal horn neuronal fibers placed below laminae I and II, surviving spinal neuronal
cell bodies and motoneuronal cells, reactive scar-forming astrocytes surrounding the lesion site and
central canal ependymal cells [39].
SCI is commonly associated with blood-spinal cord barrier (BSCB) disruption, leading to vasogenic
spinal cord edema manifesting in the accumulation of excess water in the extracellular space. However,
spinal cord edema might be caused by a number of other factors. Li et al. [65] have used the
ischemia-reperfusion injury model to study spinal cord edema. They reported that AQP1 expression is
significantly up-regulated in astrocytes in the first 12 h after injury, which was correlated with early
cytotoxic edema, whereas later up-regulation was observed in endothelial cells, which was associated
with both cytotoxic and vasogenic edema [65].
3.1.2. Changes of AQP1 Expression in Spinal Cord and Dorsal Root Ganglion in Response to
Peripheral Nerve and Tissue Damage
Peripheral nerve injury (PNI) provides an interesting model to study the changes of AQP
expression in the spinal cord. In a model of complete sciatic nerve transection, increased AQP1
expression was reported in the medial superficial part of the ipsilateral dorsal horn a week after
surgery [23]. Similarly, in a sciatic nerve cut injury model highly elevated AQP1 immunolabeling
was observed 24 h after the injury in the ipsilateral dorsal root ganglion, as well as in the dorsal and
ventral horn of the spinal cord [66]. A similar increase in AQP1 signal intensity was reported following
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sciatic nerve crush injury [66]. In contrast, in a chronic constriction injury model of the sciatic nerve,
Buffoli et al. [67] reported that the expression level of AQP1 in spinal cord and dorsal root ganglion
was not altered. Moreover, no alterations in AQP1 level in spinal cord were found in a model of tissue
damage where complete Freund’s adjuvant was intraplantary injected into a hindpaw [23].
3.1.3. AQP1 in Multiple Sclerosis (MS) and Neuromyelitis Optica Spectrum Disorders (NMOsd)
NMOsd is characterized by longitudinally extensive transverse myelitis (LETM) with or
without optic and spinal cord manifestation. It is associated with an appearance of IgG antibody
(AQP4-IgG) targeted to AQP4-expressing astrocytes which distinguishes NMOsd from multiple
sclerosis (MS) [68,69]. Additionally, several studies also suggested an emerging role of AQP1 in
NMOsd. Autoantibodies against AQP1 (AQP1-Abs) were found among patients in the high risk group
(characterized by presence of AQP4 autoantibodies with early forms of LETM or optic neuritis [70]) and
diagnosed with NMO and/or MS [71–73]. Interestingly, patients with sero-positivity for AQP4-IgG
belonging to the NMOsd group had higher reactivity to AQP1 peptides compared to the NMOsd
group with AQP4-IgG sero-negativity [71,74]. AQP1-Abs found among NMOsd patients belong to the
complement-activating IgG1 subclass that possesses affinity for the extracellular domain of AQP1 [72].
In a study by Tzartos et al. [72], five out of 42 MS patients produced AQP1-Abs and two
out of these five had spinal cord lesions. In the same study, 17 of 22 AQP1-Abs sero-positive
NMOsd patients were diagnosed with LETM and five of them were also co-diagnosed with NMO.
Misu et al. [75] analyzed AQP1 and AQP4 immunoreactivity in the specimens of brains and spinal
cords collected from 19 patients diagnosed with NMO or MS. They described six different lesion
types present in the spinal cords from patients with NMO, where AQP1 and AQP4 were expressed
in astrocytes in a distinct pattern. These lesions were localized in brain stem and spinal cord and
were classified on the basis of astrocyte loss and structural changes, axonal injury and demyelination,
polymorphonuclear leukocyte aggregations and intensity of complement deposition. For instance, in
type 1 NMO lesions, GFAP-positive astrocytes expressed AQP1 but AQP4 was undetectable. Lesions
of type 2 were characterized by fluid-filled cysts, perivascular fibrosis and presence of macrophages.
In type 3 lesions, found in the spinal cord white matter tracts, reactive astrocytes were strongly
labeled with AQP1, whereas AQP4 labeling was lost or variable. Type 4 lesions were characterized
by selective loss of AQP4 with normal AQP1 and GFAP expression and no clear signs of structural
damage. Finally, astrocytic clasmatodendrosis in NMO type 5 and 6 lesions was associated with
variable expression of both AQP1 and AQP4 and signs indicative of cell apoptosis. On the other hand,
specimens from MS patients displayed glial scar patterns characteristic of MS lesions often containing
sizable protoplasmatic multi-nuclear astrocytes. These cells had apparently lost the contact between
perivascular endfeet and glia limitans and showed strong GFAP and AQP1 labeling [75].
3.2. Aquaporin 4 (AQP4)
3.2.1. AQP4 in Spinal Cord Injury (SCI) and Syringomyelia
Aside from brain injury models, SCI is probably one of the most extensively investigated areas
examining AQP4 in the CNS. Although currently most studies on SCI are based on rodent models,
there is one study by Nesic et al. [76] describing AQP4 expression in injured human spinal cords.
Human spinal cords from three patients suffering from contusion at cervical segments C2, C5/6 and
C8, respectively, with survival time of one year for the first two cases and two years for the third case,
were analyzed. In all specimens astrocytes showed markedly increased expression of AQP4 in the
uninjured white matter. In this area GFAP expression was also retained. However, in close proximity to
the primary site of trauma-related cysts, expression of AQP4 was sparse or undetectable. Nevertheless
GFAP expression was persistent in this area, indicating that AQP4 expression was selectively decreased
in the surviving astrocytes [76].
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Similarly, AQP4-negative astrocytes were reported in rat SCI, but their presence was noted at
an earlier time point after injury. In contrast to human SCI nearly all investigated astrocytes in
rat SCI models were strongly positive for AQP4 in later phases (from one up to five months post
injury) [76]. The shift of AQP4 expression was also described in another rat SCI model where initial
down-regulation was gradually (after two weeks) changed into persistent up-regulation [77]. It was
proposed that this shift of AQP4 expression may be related to astrocyte migration and that a significant
increase in AQP4 expression could reflect astrocytes reaching the wound area. Furthermore, chronically
injured spinal cords also showed increased AQP4 levels not only at the site of injury but along the
whole spinal cord. This increase in AQP4 was observed throughout the nine-month study period [78].
Similarly, a significant increase in AQP4 immunoreactivity at 5 h, 24 h, three days and 14 days post
SCI was also observed in a rat spinal cord compression model [79]. However, despite overall AQP4
up-regulation in chronically affected spinal cords, astrocytes forming the glia limitans externa exhibited
markedly decreased AQP4 levels [77].
SCI models were frequently exploited to test potential therapeutic approaches by targeting
changes of AQP4 expression. In most of these studies conducted in both rats [80–83] and mice [84,85],
SCI contusion and compression [64,86–89] induced a common pattern of AQP4 up-regulation.
These preclinical trials have recently been reviewed in detail by Yonan and Binder [90].
Posttraumatic syringomyelia is frequently a consequence of major and minor spinal cord injury
manifested by the accumulation of CSF or fluid of different origin in cysts within the spinal cord
(known as syrinxes) [91,92]. A study by Hemley et al. [93] has shown a relation between the
increase of astrocytic AQP4 expression and the persistence of syrinxes in a rat model of posttraumatic
syringomyelia where a significant up-regulation of AQP4 was observed at three and six weeks post
injury at the level of the syrinx and in adjacent rostral and caudal levels.
In contrast to the frequently studied SCI models, there is only one report so far that describes
AQP4 expression in the spinal cord after PNI [94]. Interestingly, sciatic nerve injury evoked a long
lasting, two to threefold increase in AQP4 expression in the lumbar spinal cord that was associated
with persistent enlargement of astrocyte processes. AQP4 up-regulation, an increase in astrocyte
process volume, as well as length and number of branch points were correlated with development of
pain [94].
3.2.2. AQP4 in Neuromyelitis Optica (NMO) and Multiple Sclerosis (MS)
NMO is an autoimmune disorder characterized by the presence of AQP4-targeted autoantibodies.
This novel class of autoimmune channelopathy [95] was subsequently distinguished from NMOsd [70].
A distinctive feature of NMO is a deficiency in AQP4 expression, especially surrounding vessels
in the brainstem and spinal cord. The affected areas show prominent eosinophil infiltration and
vascular accumulation of IgM and IgG [96–98]. Furthermore, significant loss of AQP4 and GFAP has
been described in astrocytes of cultured mouse spinal cord slices following exposure to NMO-IgG
and complement. This treatment is known to result in NMO-like lesions with concurrent neuronal
demyelination [99].
Another detailed description of AQP4 expression at NMO spinal cord lesions was provided
by Misu et al. [75]. Lesions were characterized by variable loss of axons, oligodendrocytes, myelin,
complement activation and inflammatory macrophage and T cell accumulation. Astrocytes in the
area either contributed to fibrillary gliosis or presented with nuclear DNA damage or bundled and
retracted processes. Thereby, AQP4 immunoreactivity varied from decreased to undetectable [75].
Presence of anti-AQP4 autoantibodies in the serum of patients diagnosed with NMO was
positively correlated with the length of spinal cord lesions on magnetic resonance imaging (MRI) [100].
Although this correlation has not been found in a later study by Waters et al. [101], the presence
of anti-AQP4 antibodies was confirmed in 76% of NMO patients. Furthermore, Zeka et al. [102]
demonstrated in Lewis rats that T cells targeted to the AQP4268–285 epitope, together with NMO-IgG
can cause severe lesions with damaged astrocytes localized mostly in the gray matter of the spinal
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cord at the cervical and thoracic level. Noteworthy, when large numbers of AQP4268–285 specific T
cells (~2 × 107) were applied to initiate lesions, this resulted in a loss of astrocytes and AQP4 and
GFAP labeling throughout the brain and spinal cord. In contrast, when small numbers of AQP4268–285
specific T cells were used, this exclusively induced characteristic NMO-like lesions in the spinal
cord [102]. Importantly, initiation of antibody-independent characteristic NMO-like lesions caused by
AQP4-reactive T cells was observed in a mouse model [103]. Administration of AQP4-reactive T cells
to healthy wildtype mice induced infiltration of inflammatory CD3+ lymphocytes and demyelination
predominantly in the spinal cord and brain. The described AQP4-reactive T cells were acquired
by immunization of AQP4 knockout mice with human AQP456–69, AQP4135–153, and AQP4212–230
extracellular loop peptides in complete Freund’s adjuvant followed by peptide targeted in vitro
polarization of T cells into TH 17 phenotype [103].
Although NMO has initially been considered as a subtype of MS, further studies revealed
differences between the two diseases. The progression of MS and NMO lesions shows different
characteristics with regard to astrocytes. Reduced AQP4 expression was mostly observed in cases
of acute or chronic MS [104,105]. This reduction was linked to perivascular glia limitans disruption,
which is characteristic for pattern III demyelination [104]. Enlarged protoplasmatic astrocytes
with withdrawn or lost perivascular foot processes retained decreased or negative AQP4
immunoreactivity [75,104]. However, reactive astrocytes-forming MS glial scars close to the
active MS lesions were associated with highly increased expression of AQP4 in the cell body
and processes [75,97,106]. In the autoimmune encephalomyelitis-induced MS mouse model, the
white matter in the spinal cord was characterized by axonal degeneration and demyelination,
severe restructuring of neurovascular units and increased AQP4 immunoreactivity in the impaired
fibrous astrocytes. In contrast, gray matter astrocytes appeared to be much less affected [107].
These data and detailed NMO findings described above suggest that changes of AQP4 expression in
astrocytes in the lesions of MS are co-occurring events and not the primary disease target, even though
both are immune-mediated conditions, resulting in demyelination and axonal loss [97].
3.2.3. AQP4 in Amyotrophic Lateral Sclerosis (ALS)
ALS is another pathology where AQP4 expression changes and lesions of degenerated motor
neurons in motor cortex, corticospinal tracts, brain stem and spinal cord leading to muscle
paralysis [108]. Well documented features of ALS lesions are swollen and degenerated astrocytic
foot-processes surrounding neurovascular units and lining the glia limitans with markedly increased
expression of AQP4 and GFAP [109,110]. In the superoxide dismutase 1 (SOD1) mutant rat model of
ALS, a detailed analysis of spinal cord tissue sections revealed AQP4 up-regulation in the immediate
vicinity of motoneuron perikarions, which was absent in control animals [109]. Furthermore, decreased
expression of Kir4.1 channels in affected ALS astrocytes [111,112], was associated with their decreased
ability to buffer excess of K+ ions [111]. Impaired capacity of astrocytes to eliminate excessive K+ ions
together with defective glutamate clearance [113,114] is likely contributing to the degeneration and
death of motor neurons in ALS.
An additional finding is the correlation between disruption of the BBB and an increase in AQP4
in the perivascular astrocytes in the ALS models, where AQP4 was postulated as a marker for
BBB integrity [115–117]. Moreover, studies in animals have shown that signs of BSCB disruption,
like diminished levels of tight junction proteins, perivascular edema with swollen astrocytes
foot processes and leakage of Evans blue from spinal cord capillaries can precede ALS-related
neuroinflammation [118–120]. Nevertheless, the exact causes of ALS-related BBB and BSCB damage
are still unknown.
4. Implications of Physiological and Pathophysiological AQP Expression in the Spinal Cord
AQP expression and function in physiology and pathophysiology of the brain has been thoroughly
studied, whereas the role of these water channels in the spinal cord remains less well characterized.
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It is noteworthy that the expression of AQPs in the spinal cord is not identical to the expression in the
brain (Table 1). Furthermore, recent advancement points to the critical roles of water channels in the
pathogenesis of spinal cord injuries, including edema formation and development of persistent pain.
Thus, further studies are warranted to examine the critical role of AQPs in disease conditions of the
spinal cord.
Altered expression of AQPs in the spinal cord shows similarity in disease conditions. The changes
include the loss of polarity in protoplasmic astrocytes, which is often associated with withdrawal of foot
processes ensheathing the blood vessels. Other astrocytes become more reactive with increased AQP4
expression and swelling of processes. Interestingly, in most cases, AQP4 expression is up-regulated
with varying temporal characteristics, whereas only in NMO AQP4 expression is diminished,
which appears to be the direct disease target.
Changes in AQP expression in spinal cords can affect glutamate uptake and K+ buffering in
astrocytes and threaten the electro-chemical homeostasis of active neurons [121,122]. In normal
physiology, astrocytes can protect neurons from an excess of glutamate by converting it into glutamine
and thereby avoiding glutamate-induced cytotoxicity [123,124]. A number of associations that could
affect neurons by altering the water and ionic imbalance have been reported. For example, Cl−
and K+ channels, such as two-pore domain potassium channels, volume regulated anion channels
or Na+-K+-Cl− cotransporters are known to be involved in astrocyte volume regulation [125].
In addition, down-regulation of glutamate transporter GLT-1 was described in AQP4 null mice [126]
and glutamate-triggered increase in the water permeability of AQP4 was found in cultured
astrocytes [127]. Notably, it is known that the local concentration of glutamate in the spinal cord
can increase in response to PNI or SCI [128,129]. This may result in the up-regulation of both AQP1
and AQP4. Therefore, the cytotoxicity and necrosis reported in brain and spinal cords of SCI, NMO,
ALS and MS models may at least in part be mediated by altered AQP expression, in addition to the
different causes.
Loss of astrocyte polarity, in particular the loss of AQP4 in vasculature ensheathing astrocyte
processes is another feature observed in animal models of Alzheimer’s disease [130], MS [131] and
NMO [132], which is considered to be a sign of impaired BBB integrity. Likewise, damaged integrity of
both, BBB and BSCB has also been reported in patients and animal models of ALS [117] and SCI [77],
often in connection with down-regulation of tight junction proteins, degeneration of endothelial cells
and withdrawal of swollen astrocyte foot-processes and spinal cord edema. Impairment of BBB
and BSCB can facilitate penetration of inflammatory cytokines further exacerbating dysfunction and
resulting in neuronal death. Therefore, a common role of AQP4 in determining astrocyte polarity and
BBB as well as BSCB integrity requires further investigations.
Furthermore, another interesting element in spinal cord diseases is the up-regulation of AQP1
expression in astrocytes. In general, AQP1 expression in astrocytes has not been reported in healthy
spinal cords and brains of rodents and humans [41]. Thus further studies are warranted to evaluate
the significance of AQP1 up-regulation in astrocytes described in rodent models of SCI [39] and spinal
cord edema [65], as well as in human patients diagnosed with NMO [75].
Overall, more studies are needed to define the regulatory mechanisms for AQP1 and AQP4
expression in normal and disease conditions in the CNS. Moreover, the expression of AQP1 in sensory
fibers may suggest involvement in pain transmission. Additionally, the expression and potential
function of other AQPs in both spinal cord and brain remains to be clarified.
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73. Tüzün, E.; Tzartos, J.; Ekizoğlu, E.; Stergiou, C.; Zisimopoulou, P.; Çoban, A.; Shugaiv, E.; Türkoğlu, R.;
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112. Bataveljić, D.; Nikolić, L.; Milosević, M.; Todorović, N.; Andjus, P.R. Changes in the astrocytic aquaporin-4
and inwardly rectifying potassium channel expression in the brain of the amyotrophic lateral sclerosis
SOD1G93A rat model. Glia 2012, 60, 1991–2003. [CrossRef] [PubMed]
113. Spencer, D.S.; Robbins, R.J.; Naftolin, F. Decreased glutamate transport by the brain and spinal cord in
amyotrophic lateral sclerosis. N. Engl. J. Med. 1992, 327, 1541–1548. [CrossRef] [PubMed]
114. Trotti, D.; Aoki, M.; Pasinelli, P.; Berger, U.V.; Danbolt, N.C.; Brown, R.H.; Hediger, M.A. Amyotrophic lateral
sclerosis-linked glutamate transporter mutant has impaired glutamate clearance capacity. J. Biol. Chem. 2001,
276, 576–582. [CrossRef] [PubMed]
115. Nicaise, C.; Soyfoo, M.S.; Delporte, C.; Pochet, R. Aquaporin-4 as a potential marker of BBB disruption in
ALS models. Amyotroph. Lateral Scler. 2010, 11, 253–254. [CrossRef] [PubMed]
116. Garbuzova-Davis, S.; Saporta, S.; Sanberg, P.R. Implications of blood-brain barrier disruption in ALS.
Amyotroph. Lateral Scler. 2008, 9, 375–376. [CrossRef] [PubMed]
117. Garbuzova-Davis, S.; Sanberg, P.R. Blood-CNS barrier impairment in ALS patients versus an animal model.
Front. Cell. Neurosci. 2014, 8, 21. [CrossRef] [PubMed]
118. Garbuzova-Davis, S.; Saporta, S.; Haller, E.; Kolomey, I.; Bennett, S.P.; Potter, H.; Sanberg, P.R. Evidence of
compromised blood-spinal cord barrier in early and late symptomatic SOD1 mice modeling ALS. PLoS ONE
2007, 2, e1205. [CrossRef] [PubMed]
119. Zhong, Z.; Deane, R.; Ali, Z.; Parisi, M.; Shapovalov, Y.; Banion, O.; Stojanovic, K.; Sagare, A.; Boillee, S.;
Cleveland, D.W.; et al. ALS-causing SOD1 mutants generate vascular changes prior to motor neuron
degeneration. Nat. Neurosci. 2008, 11, 420–422. [CrossRef] [PubMed]
120. Miyazaki, K.; Ohta, Y.; Nagai, M.; Morimoto, N.; Kurata, T.; Takehisa, Y.; Ikeda, Y.; Matsuura, T.; Abe, K.
Disruption of neurovascular unit prior to motor neuron degeneration in amyotrophic lateral sclerosis.
J. Neurosci. Res. 2011, 89, 718–728. [CrossRef] [PubMed]
121. Kucheryavykh, Y.V.; Kucheryavykh, L.Y.; Nichols, C.G.; Maldonado, H.M.; Baksi, K. Downregulation of Kir4.
1 inward rectifying potassium channel subunits by RNAi impairs potassium transfer and glutamate uptake
by cultured cortical astrocytes. Glia 2007, 281, 274–281. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2016, 17, 2050 18 of 18
122. Tang, X.; Taniguchi, K.; Kofuji, P. Heterogeneity of Kir4. 1 channel expression in glia revealed by mouse
transgenesis. Gila 2009, 1715, 1706–1715.
123. Van Damme, P.; Bogaert, E.; Dewil, M.; Hersmus, N.; Kiraly, D.; Scheveneels, W.; Bockx, I.; Braeken, D.;
Verpoorten, N.; Verhoeven, K.; et al. Astrocytes regulate GluR2 expression in motor neurons and their
vulnerability to excitotoxicity. Proc. Natl. Acad. Sci. USA 2007, 104, 14825–14830. [CrossRef] [PubMed]
124. Zou, J.; Wang, Y.X.; Dou, F.F.; Lü, H.Z.; Ma, Z.W.; Lu, P.H.; Xu, X.M. Glutamine synthetase down-regulation
reduces astrocyte protection against glutamate excitotoxicity to neurons. Neurochem. Int. 2010, 56, 577–584.
[CrossRef] [PubMed]
125. Benesova, J.; Rusnakova, V.; Honsa, P.; Pivonkova, H.; Dzamba, D.; Kubista, M.; Anderova, M. Distinct
expression/function of potassium and chloride channels contributes to the diverse volume regulation in
cortical astrocytes of GFAP/EGFP mice. PLoS ONE 2012, 7, e29725. [CrossRef] [PubMed]
126. Zeng, X.N.; Sun, X.L.; Gao, L.; Fan, Y.; Ding, J.H.; Hu, G. Aquaporin-4 deficiency down-regulates glutamate
uptake and GLT-1 expression in astrocytes. Mol. Cell. Neurosci. 2007, 34, 34–39. [CrossRef] [PubMed]
127. Gunnarson, E.; Zelenina, M.; Axehult, G.; Song, Y.; Bondar, A.; Krieger, P.; Brismar, H.; Zelenin, S.; Aperia, A.
Identification of a molecular target for glutamate regulation of astrocyte water permeability. Glia 2008, 596,
587–596. [CrossRef] [PubMed]
128. Inquimbert, P.; Bartels, K.; Babaniyi, O.B.; Barrett, L.B.; Tegeder, I.; Scholz, J. Peripheral nerve injury produces
a sustained shift in the balance between glutamate release and uptake in the dorsal horn of the spinal cord.
Pain 2012, 29, 2422–2431. [CrossRef] [PubMed]
129. Xu, G.; Hughes, M.G.; Ye, Z.; Hulsebosch, C.E.; Mcadoo, D.J. Concentrations of glutamate released following
spinal cord injury kill oligodendrocytes in the spinal cord. Exp. Neurol. 2004, 187, 329–336. [CrossRef]
[PubMed]
130. Yang, J.; Lunde, L.K.; Nuntagij, P.; Oguchi, T.; Camassa, L.M.A.; Nilsson, L.N.G.; Lannfelt, L.; Xu, Y.;
Amiry-Moghaddam, M.; Ottersen, O.P.; et al. Loss of astrocyte polarization in the Tg-ArcSwe mouse model
of Alzheimer’s disease. J. Alzheimer’s Dis. 2011, 27, 711–722.
131. Wolburg-buchholz, K.; Mack, A.F.; Engelhardt, B.; Wolburg, H.; Pfeiffer, F.; Steiner, E. Loss of astrocyte
polarity marks blood—Brain barrier impairment during experimental autoimmune encephalomyelitis.
Acta Neuropathol 2009, 118, 219–233. [CrossRef] [PubMed]
132. Misu, T.; Fujihara, K.; Kakita, A.; Konno, H.; Nakamura, M.; Watanabe, S.; Nakashima, I. Loss of aquaporin 4
in lesions of neuromyelitis optica: Distinction from multiple sclerosis. Brain 2007, 130, 1224–1234. [CrossRef]
[PubMed]
© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
